Lipocine (NASDAQ:LPCN) Stock Price Passes Above 50 Day Moving Average – Should You Sell?

Lipocine Inc. (NASDAQ:LPCN) shares passed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $3.48 and traded as high as $8.29. Lipocine shares last traded at $8.03, with a volume of 421,913 shares trading hands.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on LPCN. Weiss Ratings reissued a “sell (d-)” rating on shares of Lipocine in a research report on Monday. HC Wainwright cut their price target on shares of Lipocine from $8.00 to $7.00 and set a “buy” rating for the company in a report on Thursday, November 13th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $7.00.

Lipocine Stock Performance

The firm has a market capitalization of $45.02 million, a P/E ratio of -7.95 and a beta of 1.03. The firm has a 50-day moving average of $3.58 and a 200-day moving average of $3.24.

Lipocine (NASDAQ:LPCN) last posted its earnings results on Thursday, November 6th. The specialty pharmaceutical company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.03). Lipocine had a negative return on equity of 30.65% and a negative net margin of 126.67%.The firm had revenue of $0.11 million for the quarter, compared to analysts’ expectations of $0.24 million.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Lipocine stock. Citadel Advisors LLC acquired a new position in Lipocine Inc. (NASDAQ:LPCN) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 14,247 shares of the specialty pharmaceutical company’s stock, valued at approximately $41,000. Citadel Advisors LLC owned approximately 0.26% of Lipocine at the end of the most recent reporting period. Hedge funds and other institutional investors own 9.11% of the company’s stock.

Lipocine Company Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.